On April 6, 2018 the Center for Medicare Advocacy and Florida Health Justice Project filed a lawsuit in U.S. District Court for the Southern District of Florida on behalf of a 49-year-old beneficiary seeking Medicare coverage for his … [Read more...] about The Center for Medicare Advocacy and Florida Health Justice Project Sue to Obtain “Off-label” Part D Prescription Drug Coverage for Beneficiary
Medicare Part D / Prescription Drugs
Center for Medicare Advocacy and Florida Health Justice Project Sue to Obtain “Off-label” Part D Prescription Drug Coverage for Beneficiary
April 16, 2018 For Immediate ReleaseContact: Center for Medicare Advocacy – Kata Kertesz: KKertesz@MedicareAdvocacy.org, 202-293-5760 Florida Health Justice Project – Miriam Harmatz: Harmatz@FloridaHealthJustice.org, … [Read more...] about Center for Medicare Advocacy and Florida Health Justice Project Sue to Obtain “Off-label” Part D Prescription Drug Coverage for Beneficiary
Center for Medicare Advocacy Submits Comments to CMS’ Draft 2019 Call Letter for Medicare Advantage and Part D
On February 1, 2018, the Centers for Medicare & Medicaid Services (CMS) issued its draft 2019 Call Letter, an annual set of proposed rules, guidelines and clarifications for Part C Medicare Advantage (MA) and Part D plans that wish to participate … [Read more...] about Center for Medicare Advocacy Submits Comments to CMS’ Draft 2019 Call Letter for Medicare Advantage and Part D
Bill to Control Medicare Prescription Drug Costs Introduced
Representative Sandy Levin recently introduced the Protecting Medicare from Excessive Price Increases Act, which would require prescription drug manufacturers to pay a rebate when the price of their Part B drug increases faster than inflation. … [Read more...] about Bill to Control Medicare Prescription Drug Costs Introduced
Center Urges CMS to Preserve and Strengthen Consumer Protections in Medicare Advantage and Part D
As noted in a previous Alert, the Center for Medicare & Medicaid Services (CMS) recently finalized their 2018 Call Letter. In the same document, CMS issued a Request for Information regarding ideas for “regulatory, sub-regulatory, … [Read more...] about Center Urges CMS to Preserve and Strengthen Consumer Protections in Medicare Advantage and Part D
Center Comments on Medicare Advantage and Part D “Transformation Ideas”
April 24, 2017VIA ELECTRONIC SUBMISSION PartCDcomments@cms.hhs.govSeema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Baltimore, MD 21244Re: … [Read more...] about Center Comments on Medicare Advantage and Part D “Transformation Ideas”
Preview – 2017 Part D Standard Benefit & Other Threshold Amounts
Note: The amounts in this table do not apply to beneficiaries who have the Part D Low Income Subsidy (“Extra Help”) Annual Deductible Maximum $400 Initial Coverage … [Read more...] about Preview – 2017 Part D Standard Benefit & Other Threshold Amounts
The Center’s Long-Time Concerns Gain Attention
Prescription Drug PricingAn excellent and well-timed (given #Epi-gate) article appeared in this week’s Journal of the American Medical Association discussing the reason drug costs are so high in the U.S. According to the article, the major … [Read more...] about The Center’s Long-Time Concerns Gain Attention
Medicare Part D and Off-Label Rx Denials
In the last 18 months, the Center for Medicare Advocacy, and other advocates around the country, have received many, many calls from older and disabled beneficiaries who can no longer obtain coverage for the Lidocaine Patch 5% from their Part D … [Read more...] about Medicare Part D and Off-Label Rx Denials
Federal Court Issues Favorable Off-label Part D Drug Coverage Decision
The Medicare Advocacy Project of Greater Boston Legal Services recently received a favorable decision from the U.S. District Court in Massachusetts for “off-label” coverage of the drug Dronabinol. This is a welcome development given … [Read more...] about Federal Court Issues Favorable Off-label Part D Drug Coverage Decision